Status
Enrolling
Condition
Myocardial Infarction
Description
A randomized, double –blind, placebo controlled, parallel group, multinational trial, to assess the prevention of thrombotic events with Ticagrelor compared to placebo on a background of Acetyl Salicylic Acid (ASA) therapy in patients with history of myocardial infarction
Purpose
The purpose of this study is to see if a new investigational drug called Ticagrelor given twice daily in addition to current Acetyl Salicylic Acid (ASA) therapy will decrease the frequency of cardiovascular events
Phase
III
Key Inclusion Criteria
- Men and women 50 years of age or older.
- Documented history of heart attack within 1 to 3 years ago and have at least 1 of the following risk factors:
- Age ≥65 years
- Diabetes requiring medication
- Documented history of a second prior MI greater than 1 year ago
- Angiographic evidence of multivessel coronary artery disease (CAD) and or Chronic, non-end stage renal dysfunction
Key Exclusion Criteria
- Persons who are being treated with agents inhibiting blood clotting if the agent cannot be stopped at study start
- Persons who have planned coronary, cerebrovascular, or peripheral arterial revascularization (invasive surgery) at study start
ClinicalTrials.gov Identifier
NCT01225562
